跳至主要内容
临床试验/NCT02517827
NCT02517827Unknown不适用

Percutaneous Intervention Versus Surgery in the Treatment of Common Femoral Artery Lesions A Prospective, Multi-centre, Randomised Study

Herz-Zentrums Bad Krozingen2 个研究点 分布在 1 个国家目标入组 306 人开始时间: 2017年8月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
306
试验地点
2
主要终点
Primary patency

研究概览

简要总结

The endovascular therapy prevailed in nearly all regions of peripheral artery disease over open surgery techniques. However, in treatment of the common femoral artery vascular surgery is still the gold standard of therapy. One-year patency rates are between 90% and 95%. Today, only in selected cases an endovascular procedure for common femoral artery diseases is recommended.

The primary objective of this study is to compare the performance of directional atherectomy and drug-coated balloon angioplasty over vascular surgery in common femoral artery lesions in a prospective, multi-center, randomized clinical trial.

详细描述

Multicenter, prospective, randomized study to be conducted in centers in Europe. A total of 260 subjects will be entered into the study and will be randomized on a 1:1 basis to either directional atherectomy and drug coated balloon angioplasty (optional with stentimplantation), and surgical endarterectomy for treatment in symptomatic (Rutherford-Becker class 2 to 4) common femoral artery disease. All subjects will undergo repeat duplex-ultrasound measurements 6, 12, and 24 months to assess the primary endpoint of Binary Restenosis. Follow-up visits are scheduled 6, 12, and 24 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject must be between 21 and 85 years old;
  • Female of childbearing potential must have a negative pregnancy test within 10 days prior to index procedure and utilize reliable birth control until completion of the 12-month angiographic evaluation;
  • Clinical diagnosis of symptomatic peripheral artery disease defined by Rutherford 2, 3, or 4;
  • Common femoral artery (CFA) stenosis (including CFA bifurcation) >70% (visual estimate) or occlusion; Additional non-target lesion(s) in remaining non-target vessel(s), except ipsilateral iliac arteries, can be treated at the physician´s discretion;
  • At least one vessel outflow (infrapopliteal arteries) to the foot (without stenosis >50%).
  • Endovascular Procedure: successful target lesion crossing of the guidewire (guidewire located intraluminally);
  • Non-target lesion interventions (TASC A and B) to restore adequate blood flow, in the same index procedure are allowed. This intervention must be prior to the treatment of the study lesion and successful;
  • Willing to comply with the specified follow-up evaluation;
  • Written informed consent prior to any study procedures.

排除标准

  • Ipsilateral significant (>50%) stenosis of the iliac arteries.
  • Significant (>50%) stenosis of all infrapopliteal arteries, no patent artery to the foot.
  • Angiographic evidence of thrombus within target vessel;
  • Thrombolysis within 72 hours prior to the index procedure;
  • In-Stent restenosis or restenosis of the native common femoral artery.
  • Aneurysm in the abdominal aorta or iliac arteries;
  • Concomitant hepatic insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy;
  • Recent MI or stroke < 30 days prior to the index procedure;
  • Life expectancy less than 24 months;
  • Known or suspected active infection at the time of the index procedure;
  • Known or suspected allergies or contraindications to aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, or contrast agent;
  • Any significant medical condition which, in the investigator´s opinion, may interfere with the subject´s optimal participation in the study;
  • The subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.

研究组 & 干预措施

Surgery

Active Comparator

Common femoral artery (target lesion) to be treated with open, surgical endarterectomy

干预措施: Open, surgical endarterectomy (Procedure)

Endovascular procedure

Active Comparator

Common femoral artery (target lesion) to be treated with directional atherectomy and paclitaxel-coated balloon angioplasty. Optional: stentimplantation.

干预措施: Atherectomy and paclitaxel-coated balloon angioplasty (Device)

结局指标

主要结局

Primary patency

时间窗: 12 month

Primary patency of the common femoral artery defined as freedom from target lesion restenosis (luminal narrowing of ≥50%) detected with duplex-ultrasound. The definition of a 50% restenosis is based on the peak systolic velocity ratio \>2.4.

次要结局

  • target lesion revascularisation(6, 12, and 24 month)
  • Primary patency(24 month)

研究者

发起方
Herz-Zentrums Bad Krozingen
申办方类型
Other
责任方
Principal Investigator
主要研究者

Aljoscha Rastan

MD, Executive senior physician

Herz-Zentrums Bad Krozingen

研究点 (2)

Loading locations...

相似试验